Patient A | Parexel

Explore patient pathways to CAR-T trial participation

Patient Pathways

Patient A

Does not have a referral from a HCP

Patient Outcome

Patient A is excluded from trial enrollment as there is a lack of HCP awareness.

CAR-T therapy is still a novel treatment, so referrals can be limited. Trial locations are at prominent academic research centers, restricting access to wider patient populations

What we learned about access to, and engagement with CAR-T trials

A lack of awareness from HCPs impacts patient referrals:

Cell and Gene therapies are still in their infancy, so referring providers may be less familiar with, or less confident in recommending CAR-T due to restrictive loc ation access. This can directly impact patients' awareness of CAR-T as a care option.

Referring physicians can misidentify canidates that are not appropriate and under identify appropriate patients which may explain why the update of CAR-T has been so slow and less than gratifying

The HCP's perspective

Our Methodology

Literature review of CAR-T and related clinical trial challenges, internal Parexel presentations

4 Qualitative HCP in-depth interviews
Hematology/Oncology, Clinical Trial Coordinator, Parexel medical Directors and Parexel Nurse Advisor

104 Quantitative surveys
patients familiar with or who have received CAR-T therapy for their hematological malignancy

5 Qualitative patient and caregiver in-depth interviews
patients who have received CAR-T in a clinical trial

Learn what's possible now

Stay current with novel thinking and actionable insights from our experts.

Start a conversation

Learn more about Parexel's cell and gene therapy research

At Parexel, we deliver innovative trial designs, built on a deep understanding of the patient journey. Our Cell and Gene Therapy Center of Excellence aggregates best practices from across the development lifecycle to help our customers navigate frequently changing regulatory hurdles and accelerate the treatment journey to patients. Parexel supports sponsors to take control of their regulatory path and reduce compliance risks to deliver a faster, smarter route from proof of concept to marketing authorization.

Accelerate your cell and gene therapy development and maximize the chances of market success with Parexel.

Find out more